Drug Profile
Research programme: metabolic disorders therapy - Alize Pharma
Alternative Names: AZP-03 program - Alize PharmaLatest Information Update: 17 Feb 2010
Price :
$50
*
At a glance
- Originator Alize Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 17 Feb 2010 Discontinued for Metabolic disorders in France (unspecified route)
- 13 Feb 2009 Early research in Metabolic disorders in France (unspecified route)